Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ALDH2 | P05091 | 2/20 | 0.45 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.45 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.43 |
| ▸ | ALDH1B1 | P30837 | 1/20 | 0.43 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | KCNA2 | P16389 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9098003 | 0.98 | ADORA3 (0.48) | CYP3A4ADORA3HPGDCYP1A1THRB | |
| SCHEMBL1372243 | 0.91 | HPGD (0.43) | CYP3A4ADORA3HPGDCYP1A1THRB | |
| SCHEMBL6554781 | 0.81 | SRC (0.45) | CYP3A4ADORA3HPGDCYP1A1THRB | |
| SCHEMBL30054772 | 0.77 | ALDH2 (0.50) | CYP3A4ADORA3HPGDCYP1A1THRB | |
| SCHEMBL25393535 | 0.77 | ALDH2 (0.50) | CYP3A4ADORA3HPGDCYP1A1THRB | |
| SCHEMBL6802035 | 0.74 | ALDH1A1 (0.70) | CYP3A4ADORA3HPGDCYP1A1THRB | |
| SCHEMBL6994969 | 0.72 | ALDH2 (0.56) | CYP3A4ADORA3HPGDCYP1A1ALDH2 | |
| SCHEMBL17525029 | 0.71 | ALDH2 (0.59) | ADORA3HPGDTHRBMAPK1ALDH2 | |
| SCHEMBL3975535 | 0.71 | ADORA3 (0.66) | CYP3A4ADORA3HPGDCYP1A1THRB | |
| SCHEMBL9277301 | 0.70 | ALDH2 (0.63) | HPGDTHRBMAPK1ALDH2ALDH1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 785 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388642-A1 | COMPOSITIONS AND METHODS FOR IMPROVED NK CELL THERAPIES | CERUS CORPORATION (US) | 2025-12-25 | — | — | US | claimed |
| US-20230071100-A1 | DEVICE OF GENERATING INACTIVATED VIRUSES AND KILLING RESPIRATORY VIRUSES IN EXHALED AIR IN REAL TIME AND METHOD THEREOF | CHIUEH TZONG SHI (TW) | 2023-03-09 | — | — | US | claimed |
| US-20200352856-A1 | Compositions for Topical Application of Medicaments onto a Mammalian Body Surface | BLANCHARD JAMES (US) | 2020-11-12 | — | — | US | claimed |
| US-10821075-B1 | Compositions for topical application of a medicaments onto a mammalian body surface | BLANCHARD JAMES (US) | 2020-11-03 | — | — | US | claimed |
| CN-111065415-A | Platform for local delivery of pharmaceutical agents and method of formulating same | 詹姆斯·布兰查德 | 2020-04-24 | — | — | CN | claimed |
| WO-2019014380-A1 | PLATFORMS FOR TOPICAL DELIVERY OF MEDICAMENTS AND METHODS FOR THEIR PREPARATION | BLANCHARD JAMES (US) | 2019-01-17 | — | — | WO | claimed |
| WO-2017115382-A1 | CUSTOMIZED TOPICAL COMPOSITION | BANERJI SANJAY (IN) | 2017-07-06 | — | — | WO | claimed |
| US-20160235708-A1 | TOPICAL PIGMENTORY COMPOSITION | BANERJI SANJAY (IN) | 2016-08-18 | — | — | US | claimed |
| WO-2015049694-A9 | TOPICAL PIGMENTORY COMPOSITION | BANERJI SANJAY (IN) | 2016-02-04 | — | — | WO | claimed |
| US-9034881-B2 | Treatment for vitiligo | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-19 | — | — | US | claimed |
| US-5462733-A | Irradiating a suspension of cells with visible light in the presence of psoralen | YALE UNIVERSITY (US) | 1995-10-31 | — | — | US | claimed |
| EP-0668772-A1 | SPECIFIC IMMUNE SYSTEM MODULATION | YALE UNIVERSITY (US) | 1995-08-30 | — | — | EP | claimed |
| WO-1995003814-A1 | CELLULAR VACCINE AND METHODS OF USE FOR THE TREATMENT OF SOLID TUMOR MALIGNANCIES | YALE UNIVERSITY (US) | 1995-02-09 | — | — | WO | claimed |
| WO-1995000631-A1 | SYSTEM FOR VIRAL INACTIVATION OF BLOOD | NEW YORK BLOOD CENTER, INC. (US) | 1995-01-05 | — | — | WO | claimed |
| WO-1994017812-A1 | IMMUNE SYSTEM MODULATION USING PSORALENS ACTIVATED WITH VISIBLE LIGHT | YALE UNIVERSITY (US) | 1994-08-18 | — | — | WO | claimed |
| WO-1994011016-A1 | SPECIFIC IMMUNE SYSTEM MODULATION | YALE UNIVERSITY (US) | 1994-05-26 | — | — | WO | claimed |
| US-5300097-A | Fiber optic psoriasis treatment device | LERNER MEDICAL DEVICES, INC. | 1994-04-05 | — | — | US | claimed |
| WO-1993007748-A2 | LASER-BASED INHIBITION OF SMOOTH MUSCLE CELL HYPERPROLIFERATION | THE GENERAL HOSPITAL CORPORATION (US) | 1993-04-29 | — | — | WO | claimed |
| WO-1992017208-A1 | AN EMOLLIENT COMPOSITION | BIOGLAN LABORATORIES LTD. (GB) | 1992-10-15 | — | — | WO | claimed |
| EP-0319957-A2 | A method for modifying the surface of a polymer | GLUETECH APS (DK) | 1989-06-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388642-A1 | COMPOSITIONS AND METHODS FOR IMPROVED NK CELL THERAPIES | KLRK1, MICA, PBK | CYP3A4 4513/4885ADORA3 650/4885HPGD 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.